ClinicalTrials.gg
CompletedNCT02568423Updated Feb 8, 2024Results posted

A Study of Mirikizumab (LY3074828) in Healthy Participants

A Phase 1 interventional study of Mirikizumab - IV and Mirikizumab - SC in Healthy, sponsored by Eli Lilly and Company. Completed at 1 site in United States. Open to participants aged 20 Years to 64 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-02-08.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
51
Allocation
Randomized
Ages
20 Years to 64 Years
Sex
All
01

Study summary

The main purpose of this study is to explore the safety and tolerability of mirikizumab in healthy Japanese and Caucasian participants. The study will also estimate how much mirikizumab gets into the blood stream and how long it takes the body to remove it. The study is expected to last about 16 weeks for each participant.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.

Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Are overtly healthy males or females, as determined by medical history and physical examination.
  • Are first generation Japanese or are Caucasian.
  • Have a (BMI) of 18.0 kilograms per square meter (kg/m2) to 32.0 kg/m2, inclusive, at screening.
  • Have a body weight of 40.0 kg or higher for Cohorts 1, 2, 3 and 4, and 48.0 kg or higher for Cohort 5 and 6.

Exclusion criteria

Exclusion Criteria:

  • Have had symptomatic herpes zoster within 3 months of screening.
  • Show evidence of active or latent tuberculosis (TB), as documented by medical history and examination, chest x-rays (posterior anterior and lateral), and TB testing.
  • Have received (s) within 1 month of screening or intend to during the study.
  • Are .
  • Have received treatment with biologic agents (such as monoclonal antibodies, including marketed drugs) within 3 months or 5 half-lives (whichever is longer) prior to dosing.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
51 participants (actual)

Study arms

  • Experimental
    Mirikizumab IV

    Participants received 200mg Mirikizumab by intravenously.

    Drug: Mirikizumab - IV

  • Experimental
    Mirikizumab SC

    Participants received single dose of either 60mgor 200mg 0r 600mg or 1200mg or 2400mg Mirikizumab by subcutaneously.

    Drug: Mirikizumab - SC

  • Placebo comparator
    Placebo IV

    Participants received placebo by intravenously.

    Drug: Placebo - IV

  • Placebo comparator
    Placebo SC

    Participants received placebo by subcutaneously.

    Drug: Placebo - SC

Interventions

  • Administered IV

    Also known as: LY3074828

  • Administered SC

    Also known as: LY3074828

  • DrugPlacebo - IV

    Administered IV

  • DrugPlacebo - SC

    Administered SC

06

What researchers measure

Primary outcomes

  1. Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration

    SAE is any adverse event (AE) from this study that results in one of the following outcomes: 1. death 2. initial or prolonged inpatient hospitalization 3. a life-threatening experience (that is, immediate risk of dying) 4. persistent or significant disability/incapacity 5. congenital anomaly/birth defect 6. considered significant by the investigator for any other reason

    Time frame: Baseline through Day 85

Secondary outcomes

  1. Pharmacokinetics (PK): Maximum Concentration (Cmax) of Mirikizumab

    Pharmacokinetics (PK): Maximum Concentration (Cmax) of Mirikizumab.

    Time frame: Day 1: 0 (pre dose), end of infusion, 2, 6, 24, 72, 168, 240, 336, 504, 672, 1008, 1344, 1680, 2016 hr post dose for IV administration; Day 1: 0 (pre dose), 6, 24, 72, 168, 240, 336, 504, 672, 1008, 1344, 1680, 2016 hr post dose for SC administration

  2. Pharmacokinetics: Area Under the Concentration (AUC) Curve From Time Zero to Infinity of Mirikizumab

    Pharmacokinetics: Area Under the Concentration (AUC) Curve from Time Zero to Infinity of Mirikizumab.

    Time frame: Day 1: 0 (pre dose), end of infusion, 2, 6, 24, 72, 168, 240, 336, 504, 672, 1008, 1344, 1680, 2016 hr post dose for IV administration; Day 1: 0 (pre dose), 6, 24, 72, 168, 240, 336, 504, 672, 1008, 1344, 1680, 2016 hr post dose for SC administration

07

Results

Posted Feb 8, 2024

Participant flow

Participant flow — Overall Study
MilestonePlacebo Subcutaneous (SC)Placebo IV60mg Mirikizumab IV200mg Mirikizumab SC200mg Mirikizumab IV600mg Mirikizumab IV1200mg Mirikizumab IV2400mg Mirikizumab IV
Started210666966
Received at least one dose of study drug210666966
Completed28666866
Not completed02000100
Withdrew: Lost to follow-up02000000
Withdrew: Physician decision00000100

Outcome measures

PrimaryNumber of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration

SAE is any adverse event (AE) from this study that results in one of the following outcomes: 1. death 2. initial or prolonged inpatient hospitalization 3. a life-threatening experience (that is, immediate risk of dying) 4. persistent or significant disability/incapacity 5. congenital anomaly/birth defect 6. considered significant by the investigator for any other reason

Time frame:
Baseline through Day 85
Reported as:
Count of participants · Participants
Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
ParticipantsPlacebo SCPlacebo IV60mg Mirikizumab IV200mg Mirikizumab IV200mg Mirikizumab SC600mg Mirikizumab IV1200mg Mirikizumab IV2400mg Mirikizumab IV
Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration00000000
SecondaryPharmacokinetics (PK): Maximum Concentration (Cmax) of Mirikizumab

Pharmacokinetics (PK): Maximum Concentration (Cmax) of Mirikizumab.

Time frame:
Day 1: 0 (pre dose), end of infusion, 2, 6, 24, 72, 168, 240, 336, 504, 672, 1008, 1344, 1680, 2016 hr post dose for IV administration; Day 1: 0 (pre dose), 6, 24, 72, 168, 240, 336, 504, 672, 1008, 1344, 1680, 2016 hr post dose for SC administration
Reported as:
Geometric mean · Microgram per Milliliter (μg/mL)
Pharmacokinetics (PK): Maximum Concentration (Cmax) of Mirikizumab
Microgram per Milliliter (μg/mL)60mg Mirikizumab IV200mg Mirikizumab SC200mg Mirikizumab IV600mg Mirikizumab IV1200mg Mirikizumab IV2400mg Mirikizumab IV
Pharmacokinetics (PK): Maximum Concentration (Cmax) of Mirikizumab23.1 ± 911.8 ± 3978.8 ± 13250 ± 16454 ± 11985 ± 20
SecondaryPharmacokinetics: Area Under the Concentration (AUC) Curve From Time Zero to Infinity of Mirikizumab

Pharmacokinetics: Area Under the Concentration (AUC) Curve from Time Zero to Infinity of Mirikizumab.

Time frame:
Day 1: 0 (pre dose), end of infusion, 2, 6, 24, 72, 168, 240, 336, 504, 672, 1008, 1344, 1680, 2016 hr post dose for IV administration; Day 1: 0 (pre dose), 6, 24, 72, 168, 240, 336, 504, 672, 1008, 1344, 1680, 2016 hr post dose for SC administration
Reported as:
Geometric mean · Microgram day per milliliter (μg*day/mL)
Pharmacokinetics: Area Under the Concentration (AUC) Curve From Time Zero to Infinity of Mirikizumab
Microgram day per milliliter (μg*day/mL)60mg Mirikizumab IV200mg Mirikizumab SC200mg Mirikizumab IV600mg Mirikizumab IV1200mg Mirikizumab IV2400mg Mirikizumab IV
Pharmacokinetics: Area Under the Concentration (AUC) Curve From Time Zero to Infinity of Mirikizumab148 ± 29210 ± 29539 ± 121970 ± 242900 ± 145990 ± 12

Adverse events

Collected over Up to 88 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo SC0/2 (0%)0/2 (0%)2/2 (100%)
Placebo IV0/10 (0%)0/10 (0%)5/10 (50%)
60mg Mirikizumab IV0/6 (0%)0/6 (0%)3/6 (50%)
200mg Mirikizumab SC0/6 (0%)0/6 (0%)1/6 (16.7%)
200mg Mirikizumab IV0/6 (0%)0/6 (0%)2/6 (33.3%)
600mg Mirikizumab IV0/9 (0%)0/9 (0%)1/9 (11.1%)
1200mg Mirikizumab IV0/6 (0%)0/6 (0%)0/6 (0%)
2400mg Mirikizumab IV0/6 (0%)0/6 (0%)1/6 (16.7%)
Most frequent other events
Showing 10 of 15
Most frequent other events
EventPlacebo SCPlacebo IV60mg Mirikizumab IV200mg Mirikizumab SC200mg Mirikizumab IV600mg Mirikizumab IV1200mg Mirikizumab IV2400mg Mirikizumab IV
Upper respiratory tract infectionInfections and infestations1/21/101/60/61/60/90/60/6
Post-traumatic neck syndromeInjury, poisoning and procedural complications1/20/100/60/60/60/90/60/6
Sinus arrhythmiaCardiac disorders0/20/101/60/60/60/90/60/6
FatigueGeneral disorders0/20/100/60/60/60/90/61/6
RhinitisInfections and infestations0/20/101/60/60/60/90/60/6
Urinary tract infectionInfections and infestations0/21/100/61/60/60/90/60/6
ArthralgiaMusculoskeletal and connective tissue disorders0/20/101/60/60/60/90/60/6
RashSkin and subcutaneous tissue disorders0/20/100/60/61/60/90/60/6
Infusion site extravasationGeneral disorders0/20/100/60/60/61/90/60/6
DiarrhoeaGastrointestinal disorders0/21/100/60/60/60/90/60/6

Baseline characteristics

All randomized participants.

Age, Continuous
Age, Continuous(years)Placebo SCPlacebo IV60mg Mirikizumab IV200mg Mirikizumab SC200mg Mirikizumab IV600mg Mirikizumab IV1200mg Mirikizumab IV2400mg Mirikizumab IVTotal
Mean48.5 ± 2.145.7 ± 10.649.3 ± 9.437.3 ± 8.841.7 ± 16.046.8 ± 11.937.8 ± 11.945.2 ± 6.044 ± 11
Sex: Female, Male
Sex: Female, Male(Participants)Placebo SCPlacebo IV60mg Mirikizumab IV200mg Mirikizumab SC200mg Mirikizumab IV600mg Mirikizumab IV1200mg Mirikizumab IV2400mg Mirikizumab IVTotal
Female1633553531
Male1433143120
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Placebo SCPlacebo IV60mg Mirikizumab IV200mg Mirikizumab SC200mg Mirikizumab IV600mg Mirikizumab IV1200mg Mirikizumab IV2400mg Mirikizumab IVTotal
Hispanic or Latino010302219
Not Hispanic or Latino2963674542
Unknown or Not Reported000000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Placebo SCPlacebo IV60mg Mirikizumab IV200mg Mirikizumab SC200mg Mirikizumab IV600mg Mirikizumab IV1200mg Mirikizumab IV2400mg Mirikizumab IVTotal
American Indian or Alaska Native000000000
Asian1533353326
Native Hawaiian or Other Pacific Islander000000000
Black or African American000000000
White1533343325
More than one race000000000
Unknown or Not Reported000000000
Region of Enrollment
Region of Enrollment(Participants)Placebo SCPlacebo IV60mg Mirikizumab IV200mg Mirikizumab SC200mg Mirikizumab IV600mg Mirikizumab IV1200mg Mirikizumab IV2400mg Mirikizumab IVTotal
United States21066696651
08

Study locations

1 site
  • WCCT Global
    Cypress, California 90630, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2015 to primary completion in Jul 2018, 31 months.

Results were first posted in Feb 2024, 5 years 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 2, 2015
First posted
Oct 5, 2015
StartActual
Dec 2, 2015
Primary completionActual
Jul 16, 2018
CompletionActual
Oct 24, 2018
Results first posted
Feb 8, 2024
Last update
Feb 8, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 8, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02568423
Responsible party
Sponsor
First posted
Oct 5, 2015
Start date
Dec 2, 2015
Primary completion
Jul 16, 2018
Completion
Oct 24, 2018
Results posted
Feb 8, 2024
Last update
Feb 8, 2024

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Mirikizumab

Start the discussion